Genentech, Inc.
1 DNA Way
South San Francisco
California
94080-4990
United States
Tel: 650-225-1000
Fax: 650-225-6000
Website: http://www.gene.com/
About Genentech, Inc.
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 40 years. Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. We are among the world's leading biotech companies, with multiple products on the market and a promising development pipeline. Please take this opportunity to learn about Genentech where we believe that our employees are our most important asset & are dedicated to remaining a great place to work.
Connect with us!
Being a scientist at Genentech means being a drug discoverer. Mike Varney, head of Genentech Research and Early Development, explains how this culture of innovation is helping to solve some of the hardest biomedical problems of our time.
1266 articles with Genentech, Inc.
-
Genentech’s Tecentriq in Combination With Avastin Increased Overall Survival and Progression-free Survival in People With Unresectable Hepatocellular Carcinoma
10/21/2019
First Phase III cancer immunotherapy study to show an improvement in overall survival and progression-free survival for the treatment of the most common form of liver cancer
-
Generational Priorities: What Baby Boomers, Gen-Xers and Millennials Think Makes an Ideal Employer
10/21/2019
When it comes to specific attributes, having the opportunity to do interesting and meaningful work, securing a competitive salary and having access to quality health benefits were the most important. Here are some differences when it comes to generational priorities. -
The trial met its co-primary endpoints, showing statistically significant and clinically meaningful improvements in overall survival and progression-free survival compared to standard-of-care, Bayer’s Nexavar.
-
Genentech’s Xofluza Approved for People at High Risk of Developing Flu-Related Complications
10/18/2019
Genentech’s flu medication Xofluza won a new indication for the treatment of acute, uncomplicated influenza in people 12 years of age and older who have been symptomatic for less than 48 hours and are at high risk of flu-related complications. -
Genentech Announces FDA Approval of Xofluza (Baloxavir Marboxil) for People at High Risk of Developing Influenza-Related Complications
10/17/2019
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza™ (baloxavir marboxil) for the treatment of acute, uncomplicated influenza, or flu, in people 12 years of age and older who have been symptomatic for no more than 48 hours and who are at high risk of developing flu-related complications.
-
Phase III PEMPHIX Study Shows Genentech’s Rituxan (rituximab) Superior to Mycophenolate Mofetil in Patients With Pemphigus Vulgaris
10/14/2019
40% of patients with pemphigus vulgaris (PV) achieved sustained complete remission, without the use of steroids for 16 weeks or more, when treated with Rituxan compared to 9.5% of patients on mycophenolate mofetil
-
Employees’ Perception vs. Employers’ Reality! New Research Shows the Top 3 Areas of Opportunity
10/14/2019
What makes an organization a desirable employer? Do they need to be a large company with a recognizable name? Should the organization pay their employees more than others? -
In the latest Ideal Employer Survey, BioSpace readers chimed in their thoughts on which companies across the biotech and biopharma industries were doing the most interesting and meaningful work.
-
Genentech to Present Results of First Prospective Trial Using Blood-based Next Generation Sequencing Which Successfully Identifies People for Treatment With Alecensa (Alectinib)
9/30/2019
Efficacy of Alecensa in people identified to have ALK-positive non-small cell lung cancer using liquid biopsy is consistent with efficacy in those identified by tissue analysis in the pivotal Phase III ALEX study
-
Genentech Presents Positive Phase III Results for Tecentriq (Atezolizumab) in Combination With Platinum-based Chemotherapy in People With Previously Untreated Advanced Bladder Cancer
9/30/2019
IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in people with previously untreated advanced bladder cancer
-
According to the second biennial 2019 Life Sciences Ideal Employer Report by BioSpace, the top three most important attributes cited by life sciences professionals around the world are the opportunity to do interesting and meaningful work, a competitive salary and health benefits.
-
BioSpace, the leader in life sciences news and careers, today announced that Genentech, Pfizer, Merck, Amgen and Novartis landed in the top five spots of their latest Ideal Employer report.
-
Researchers from Genentech and its parent company Roche have developed what is being called the first “deep learning model” that can predict which patients with diabetic retinopathy will progress the fastest.
-
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
-
FDA Grants Breakthrough Therapy Designation for Genentech’s Gazyva (Obinutuzumab) in Lupus Nephritis
9/18/2019
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to Gazyva® for adults with lupus nephritis.
-
A stigma remains around lung cancer and many people still regard the disease as something of a self-inflicted ailment. But that stigma is waning, new research conducted by the Inova Schar Cancer Institute and Genentech shows.
-
Clinical Catch-Up: September 9-13
9/16/2019
Last week was a busy one for clinical trial results, particularly with the European Committee for Treatment and Research in Multiple Sclerosis 2019 Congress going on. Here’s a look at some of the top clinical trial stories. -
Positive Results Announced From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme's Enhanze® Drug Delivery Technology
9/13/2019
Halozyme Therapeutics, Inc. announced that the global phase III FeDeriCa study conducted by Genentech, a member of the Roche Group, met its primary endpoint.
-
Genentech’s Fixed Dose Subcutaneous Combination of Perjeta and Herceptin Showed Non-Inferiority When Compared to Intravenous Formulations for People With HER2-Positive Breast Cancer
9/13/2019
Genentech, a member of the Roche Group, announced the Phase III FeDeriCa study met its primary endpoint.
-
Genentech Presents New Six-year Ocrevus (Ocrelizumab) Data Which Showed That Earlier Initiation and Continuation of Treatment Reduced Disability Progression in Multiple Sclerosis
9/13/2019
Genentech, a member of the Roche Group, announced longer-term data from the Phase III open-label extension studies of OPERA I, OPERA II and ORATORIO showed that patients who were treated with Ocrevus® continuously for six years or more had reduced risk of disability progression in relapsing MS and primary progressive MS.